Search by PDG name  
   

 

AKR1C3  
    


    
      Official symbol:  AKR1C3
      Full name:  aldo-keto reductase family 1 member C3
      Location:  10p15.1
      Also known as:  PGFS, KIAA0119, HSD17B5, DDX, HAKRB
      Entrez ID:  8644
      Ensembl ID:  ENSG00000196139
      Summary:  This gene encodes a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins. These enzymes catalyze the conversion of aldehydes and ketones to their corresponding alcohols by utilizing NADH and/or NADPH as cofactors. The enzymes display overlapping but distinct substrate specificity. This enzyme catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ), and the oxidation of 9alpha,11beta-PGF2 to PGD2. It may play an important role in the pathogenesis of allergic diseases such as asthma, and may also have a role in controlling cell growth and/or differentiation. This gene shares high sequence identity with three other gene members and is clustered with those three genes at chromosome 10p15-p14. Three transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Dec 2011]

    

    
  Overall distribution
    
  Tissue specific distribution
    
 
  
 
Expression restricted in 1 cancer type(s)
   

    
  Overall distribution
    
  Tissue specific distribution
    
 
Gscore (Amp):  0.31  
Gscore (Del):  0.00  
 
Recurrently amplified in 2 cancer type(s)
   

    
  Overall distribution
    
  Tissue specific distribution
    
 
Mscore:  0.00  
 
   

    
  Overall
    
  Tissue specific
    
 
Total fusion occurrence:  NA  
 
 
 

    
  Overall
    
  Tissue specific
    
     
   

    
      Functional class:  Enzyme
      JensenLab PubMed score:  388.06  (Percentile rank: 88.77%)
      PubTator score:  357.45  (Percentile rank: 91.06%)
      Target development/druggability level:  TchemThese targets have activities in ChEMBL or DrugCentral that satisfy the activity thresholds detailed below.
      Tractability (small molecule):  Discovery PrecedenceTargets with ligands; Targets with crystal structures with ligands
      Tractability (antibody):  

    







Contact us | | Terms & Conditions.
Copyright © 2020 University of Pennsylvania. All Rights Reserved.